Cited by 68Glaucoma and retinal disordersTelomeres, Telomerase, and SenescenceGenetics, Aging, and Longevity in Model Organisms

Early removal of senescent cells protects retinal ganglion cells loss in experimental ocular hypertension

Open access
Rocha, Lorena Raquel, Nguyen Huu, Viet Anh, Palomino La Torre, Claudia, Xu, Qianlan, Jabari, Mary, Krawczyk, Michal, Weinreb, Robert N., Skowronska‐Krawczyk, Dorota·2020·Aging Cell

Published version of a preprint

Abstract

Experimental ocular hypertension induces senescence of retinal ganglion cells (RGCs) that mimics events occurring in human glaucoma. Senescence-related chromatin remodeling leads to profound transcriptional changes including the upregulation of a subset of genes that encode multiple proteins collectively referred to as the senescence-associated secretory phenotype (SASP). Emerging evidence suggests that the presence of these proinflammatory and matrix-degrading molecules has deleterious effects in a variety of tissues. In the current study, we demonstrated in a transgenic mouse model that early removal of senescent cells induced upon elevated intraocular pressure (IOP) protects unaffected RGCs from senescence and apoptosis. Visual evoked potential (VEP) analysis demonstrated that remaining RGCs are functional and that the treatment protected visual functions. Finally, removal of endogenous senescent retinal cells after IOP elevation by a treatment with senolytic drug dasatinib prevented loss of retinal functions and cellular structure. Senolytic drugs may have the potential to mitigate the deleterious impact of elevated IOP on RGC survival in glaucoma and other optic neuropathies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/acel.13089

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In a mouse model, dasatinib prevented glaucoma-dependent loss of retinal functions and cellular structure.

    “Although a study in a mouse model showed that dasatinib prevented glaucoma-dependent loss of retinal functions and cellular structure, 41 a retrospective study assessing the effects of senolytic drugs on vision in 28 patients with glaucoma showed that senolytic exposure did not affect visual acuity or intraocular pressure, and did not have toxic effects.74”

    From The costs and benefits of senotherapeutics for human health (2022) · cites this paper as [41]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Rocha, L. R., Nguyen Huu, V. A., Palomino La Torre, C., Xu, Q., Jabari, M., Krawczyk, M., Weinreb, R. N., & Skowronska‐Krawczyk, D.
Affiliations
  • University of California San Diego (US)
  • Shiley Eye Institute Hamilton Glaucoma Center and Viterbi Family Department of Ophthalmology University of California, San Diego CA USA
Corresponding author
Skowronska‐Krawczyk, Dorota
Venue
Aging Cell
Publisher
Wiley
Published
2019-12-22
Volume
19
Issue
2
Pages
e13089-e13089
ISSN
  • 1474-9718 (ISSN-L)
  • 1474-9726
OpenAlex
W2996699344
Cited by
68
References
29
Citations by year
2026: 4 · 2025: 14 · 2024: 12 · 2023: 8 · 2022: 16 · 2021: 8 · 2020: 6
FWCI
7.36
Type
journal article
Language
en
Open access
Locations
  • Aging Cell (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • Research to Prevent Blindness (Special Scholar Award)
  • Glaucoma Research Foundation (Shaffer Grant)
  • National Eye Institute (P30EY022589, R01EY027011)
Topics
  • Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
  • Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
Keywords
senolytics, retinal ganglion cells, ocular hypertension, glaucoma, dasatinib, senescence-associated secretory phenotype, chromatin remodeling, apoptosis, intraocular pressure, visual evoked potentials, optic neuropathy, transgenic mouse model
MeSH terms
Dasatinib, RNA-Seq, Animals, Evoked Potentials, Visual, Mice, Inbred C57BL, Mice, Transgenic, Ocular Hypertension, Retinal Ganglion Cells, Ganciclovir, Cellular Senescence, Apoptosis, Protein Kinase Inhibitors, Mice, Gene Ontology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review